While dabrafenib can inhibit proliferation via a G1 cell cycle arrest, induce apoptosis, and cause tumor regression in BRAFV600E cells, wild-type BRAF tumor cell lines were not responsive to dabrafenib, despite MEK inhibitor sensitivity [29]. Here, MAP2K7 is linked to neoplasm.